Behavioral Intervention
Peer Resilience Champion +1 More for Burnout
This trial aims to reduce burnout among hospital workers by using two methods: a support team called Peer Resilience Champions and a detailed survey that gives personalized feedback. The study focuses on hospital staff dealing with stress from a coronavirus outbreak, helping them manage their stress better.
Popular Filters
Trials for Coronavirus Patients
Neurokinin-1 Receptor Antagonist
Tradipitant for Coronavirus
This is a randomized, double-blind placebo-controlled trial to investigate the efficacy and safety of tradipitant 85 mg orally given twice daily to treat inflammatory lung injury associated with severe or critical COVID-19 infection. On evaluation for enrollment, participant will need to meet all inclusion and exclusion criteria. If participant consents, they will be randomized 1:1 to treatment with either tradipitant 85 mg PO BID or placebo in addition to standard of care for COVID-19 infection as per the protocol at the treating hospital. NEWS 2 will be assessed at screening and daily following randomization. Inflammatory lab markers as detailed should be collected once per day in the morning, preferably at the same time every morning. All enrolled participants will have whole blood collected for whole genome sequencing.
Cell Therapy
cSVF Therapy for Post-COVID Lung Damage
This trial is a study to test a possible treatment for people who have lung damage from the COVID-19 virus. The treatment involves taking cells from the patient's own body and injecting them into the patient's bloodstream. The goal is to see if this can help improve the function of the lungs.
Virus Therapy
DAS181 for Respiratory Infections
This trial will enroll immunocompromised patients with Lower Tract parainfluenza infection to study the safety and efficacy of an investigational vaccine. A sub-study will also enroll patients with severe COVID-19.
Trials for Coronavirus Infection Patients
Selenium-containing compound
Ebselen for Moderate COVID-19
This trial is testing a possible new medication for people who have a positive PCR test for the novel coronavirus and moderate symptoms of COVID-19. The study is double-blind, meaning that neither the participants nor the researchers will know who is receiving the medication or the placebo until after the study is completed.
Phase 3 Trials
Neurokinin-1 Receptor Antagonist
Tradipitant for Coronavirus
This is a randomized, double-blind placebo-controlled trial to investigate the efficacy and safety of tradipitant 85 mg orally given twice daily to treat inflammatory lung injury associated with severe or critical COVID-19 infection. On evaluation for enrollment, participant will need to meet all inclusion and exclusion criteria. If participant consents, they will be randomized 1:1 to treatment with either tradipitant 85 mg PO BID or placebo in addition to standard of care for COVID-19 infection as per the protocol at the treating hospital. NEWS 2 will be assessed at screening and daily following randomization. Inflammatory lab markers as detailed should be collected once per day in the morning, preferably at the same time every morning. All enrolled participants will have whole blood collected for whole genome sequencing.
Virus Therapy
DAS181 for Respiratory Infections
This trial will enroll immunocompromised patients with Lower Tract parainfluenza infection to study the safety and efficacy of an investigational vaccine. A sub-study will also enroll patients with severe COVID-19.
Tyrosine Kinase Inhibitor
Imatinib for COVID-19
This trial is testing if a drug called imatinib is safe and effective for treating people hospitalized with COVID-19. The trial is randomized, which means that people are assigned by chance to either receive imatinib or a placebo (a medicine with no active ingredient). Neither the participants nor the researchers will know who is receiving imatinib or the placebo until the trial is over.
Trials With No Placebo
Cell Therapy
cSVF Therapy for Post-COVID Lung Damage
This trial is a study to test a possible treatment for people who have lung damage from the COVID-19 virus. The treatment involves taking cells from the patient's own body and injecting them into the patient's bloodstream. The goal is to see if this can help improve the function of the lungs.
Procedure
Ventilation Strategy for Acute Respiratory Distress Syndrome
This trial tests if adjusting ventilator settings based on lung measurements can reduce deaths in ARDS patients, including those with COVID-19. The goal is to provide better breathing support without causing more lung damage.
View More Related Trials
Frequently Asked Questions
Introduction to covid
What are the top hospitals conducting covid research?
In the global battle against COVID-19, top hospitals have emerged as beacons of hope and innovation. One such institution is the University of Rochester Medical Center in Rochester, New york. Despite their relatively small number of active COVID trials (3) and all-time trials (2), this hospital has made significant strides since recording its first trial in 2020. Similarly, the University of South Florida in Tampa has dedicated itself to finding effective solutions with three ongoing COVID trials and a history of two previous studies. Both these facilities have demonstrated their commitment to pushing boundaries and exploring new avenues for treatment.
Meanwhile, Hennepin County Medical Center located in Minneapolis has also stepped up to face this unprecedented challenge head-on. With three active COVID trials underway and four completed studies under its belt, this medical center stands at the forefront of innovative research within their community since initiating their inaugural trial last year.
The University of Minnesota - another prominent institution nestled in Minneapolis - joins forces by conducting three concurrent clinical trials focused on combating COVID-19 while boasting an impressive ten past investigations centered around the virus's impact on public health; they too started contributing towards understanding it from 2020 onwards.
Notably making an appearance among these renowned hospitals is Massachusetts General Hospital situated in Boston—the city rich with medical excellence—where doctors and researchers are actively engaged in three cutting-edge clinical trials aimed at conquering the pandemic that has gripped our world tightly. Having previously conducted five additional studies related to COVID-19 since embarking on research endeavors just last year.
These hospitals exemplify unwavering dedication and perseverance in tackling the current crisis. The incredible work being done across these institutions signifies extraordinary collaboration between healthcare professionals, scientists, volunteers, patients, who collectively strive for a brighter future amidst uncertain times
Which are the best cities for covid clinical trials?
When it comes to COVID clinical trials, several cities stand out as leaders in research and development. Houston, Texas leads the way with 27 active trials focusing on mRNA-1273 and Biological/Vaccine: BNT162b2 3mcg among others. Miami, Florida follows closely behind with 20 ongoing studies exploring PBI-0451 (Pomotrelvir) and Niclosamide, among other treatments. New york, New York also plays a significant role with 18 active trials investigating various treatment options like Cohort B, Arm B2P: BNT162b2 and Therapeutic Dose Anticoagulation + P2Y12 inhibitor. Additionally, Los Angeles, California and Atlanta, Georgia have notable contributions to COVID clinical trials with their respective studies on ritonavir and Biological/Vaccine: BNT162b2 3mcg. These cities collectively provide individuals affected by COVID access to cutting-edge clinical trials that pave the way for advancements in care and potential breakthroughs in combating the virus.
Which are the top treatments for covid being explored in clinical trials?
Clinical trials are actively investigating potential treatments for COVID-19, with several options showing promise. Hydroxychloroquine is currently being explored in two active trials and has been part of 22 clinical trials overall since its first listing in 2020. Another treatment gaining attention is VBI-2901a, which has one ongoing trial and was introduced to COVID research in 2022. These treatments offer hope as researchers work diligently to combat the impact of this global pandemic.
What are the most recent clinical trials for covid?
Exciting advancements are underway in the field of COVID-19 research, with recent clinical trials offering potential breakthroughs in our fight against this global pandemic. Noteworthy studies include Group i, a Phase 4 trial that aims to evaluate the effectiveness of a specific intervention for COVID-19 patients. Additionally, an inspiring Phase 1 trial investigates the use of allogeneic mesenchymal stromal cells as a treatment option for COVID-19. Another significant study involves individuals who have undergone solid organ transplants and examines their response to COVID-19 treatments in a Phase 2 trial. Further progress can be seen through Group 2 and Active, both undergoing Phase 2 trials to assess their efficacy in combatting this infectious disease. With these diverse approaches being investigated, there is hope on the horizon for improved outcomes and ultimately overcoming the challenges posed by COVID-19.
What covid clinical trials were recently completed?
Several clinical trials focusing on COVID-19 have recently concluded, representing vital steps forward in our fight against the pandemic. In August 2021, Merck Sharp & Dohme Corp. completed a trial for Molnupiravir, while Janssen Vaccines & Prevention B.V.'s Ad26.COV2.S trial also reached completion during the same month. Earlier in July 2021, James L. Kirkland's Fisetin study made significant progress as well. These trials build upon the substantial research conducted to combat COVID-19 and provide valuable insights into potential treatments and preventive measures.